{
  "eval_id": "S18",
  "eval_file": "evals/single/S18.json",
  "timestamp": "2025-09-18T16:40:14.670852Z",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "For HR+/HER2- patients who have progressed after CDK4/6 inhibitors, the label supports options like further endocrine therapy or chemotherapy, depending on prior treatments, comorbidities, and disease burden. Key caveats include careful review of the SmPC for each agent regarding prior CDK4/6 exposure and performance status. Please send the relevant label sections by email so I can confirm specifics."
}